Like France and other European countries, the vast vaccination campaign against Covid-19 has also been seriously delayed in the United States due to logistical difficulties.
Two vaccines, those from Pfizer / BioNTech and Moderna, have so far been approved for distribution by health officials in the United States, which began their vaccination campaign on December 14.
But only 2.8 million Americans had received the first dose of their Covid-19 vaccine on Friday, a far cry from the Trump administration's stated target of 20 million people vaccinated by the end of the year. year.
A delay deplored by President-elect Joe Biden, who was however determined to step up the pace.
"Let's be clear: the Biden-Harris administration will not spare any efforts to ensure that people are vaccinated," he assured Friday.
20 million cases detected
"I am more optimistic than ever, we have the most efficient teams in the world," the Democrat who will take office on January 20 also said the day before.
READ ALSO>
Covid-19 in the United States: six infographics on a third wave out of control
It must be said that in recent days, the slowness of the American vaccination campaign has considerably dampened the hopes of an eradication of the disease in the very short term.
Indeed, the outbreak of the epidemic shows no sign of slowing down in the United States, the most bereaved country in the world with more than 347,500 deaths from the virus.
The world's leading power reached the mark of 20 million cases detected on Friday.
This spectacular rebound in the epidemic since the fall has been worsened by the travel of millions of Americans for the big Thanksgiving family celebration at the end of November and the end-of-year celebrations, despite numerous calls from the authorities to stay at home .
Slowness in vaccination also observed in Europe
Vaccination campaigns are also the subject of criticism in Europe.
German doctors have complained that hospital staff is not a priority in their country.
In France, it is the slowness of the process that alarms.
Part of the difficulty is the relatively low number of orders placed by the EU for its 27 member countries, with a contract signed only in November, later than other countries.
The German company BioNTech explained that it plans to rapidly increase the production of its vaccine in Europe, developed with its American partner Pfizer, in order to fill a “gap” in the absence of other approved vaccines.
Morning essentials newsletter
A tour of the news to start the day
Subscribe to the newsletterAll newsletters
BioNTech intends in particular to run a new manufacturing unit in Marburg in Germany from February.